Business · 20/10/2005
FDA Releases Guidance on Assessing Cardiac Arrhythmias in New Drugs
The FDA has made available a guidance document outlining recommendations for assessing the potential of new drugs to cause cardiac arrhythmias, as part of the International Conference on Harmonisation's efforts to standardize pharmaceutical regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →